IRCT2015010520563N1已完成3 期
Effect of spironolactone with doses 25 and 50 mg in patients with symptomatic Systolic Heart Failure and Ejection Fraction less than 40% on quality of life and Ability and Readmission in 6 months
Ahwaz Jundishapur University of Medical Science0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Inclusion critria: patient with systolic heart failure ? symptomatic ? EF<40
- •EXCLUSION critria:Known contraindications for spironolactone or prior documented intolerance to an aldosterone receptor antagonist ?Significant laboratory abnormalities (potassium = 5.1 mmol) ? Mental disorders suspected to interact with study outcome ?Pregnant women ? Significant renal dysfunction (creatinine . 1.8 mg/dL) ? Significant hypotension (blood pressure , 90 mmHg systolic and/or ,50 mmHg diastolic ? CRT or ICD
排除标准
- 未提供
研究者
相似试验
尚未招募
3 期
Effect of 25 and 100 mg spironolactone on quality of life, ejection fraction and readmission in systolic heart failure patients with reduced ejection fractioIRCT20220404054403N1Ahvaz University of Medical Sciences94
已完成
4 期
The effect of the low-dose spironolactone in post adolescent acne: a randomized, double-blind, placebo-controlled trial.acne vulgaris in women who age from 25ᇁ years oldspironolactonepostadolescent acneTCTR20190417004Faculty of Medicine, Chulalongkorn University62
招募中
2 期
Comparing the effectiveness of spironolactone solution with clindamycin solution in patients with acneMild to moderate acne vulgaris.Acne vulgarisL70.0IRCT20120524009844N12Tabriz University of Medical Sciences60
已完成
不适用
combination therapy trial in COVID-19 patientsCOVID19.COVID-19, virus identifiedU07.1IRCT20201003048904N2Boushehr University of Medical Sciences200
已完成
1 期
Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg TabletsHealthyNCT01083290Orion Corporation, Orion Pharma14